Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AAV2-hAADC

Gene therapy (AAV vector) · Gene replacement · developed by Neurocrine Biosciences

Phase 2 Most advanced trial (none active)
1 Registered trials

What is AAV2-hAADC?

AAV2-hAADC is an adeno-associated virus serotype 2 gene therapy carrying the human aromatic amino acid decarboxylase (DDC) gene, delivered by intracerebral infusion. It is being studied in aromatic amino acid decarboxylase deficiency, a condition caused by a defect in that gene.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy (AAV vector)
Mechanism
Gene replacement
Therapy area
Metabolic, Neurology
Developer
Neurocrine Biosciences
In trials of
PTCT
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02926066 Phase 2 Aromatic Amino Acid Decarboxylase Deficiency Completed PTCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Aromatic Amino Acid Decarboxylase Deficiency

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.